Evolent Health, Inc. (NYSE: EVH – Get Rating) received an average rating of “Moderate Buy” from the ten research companies currently covering the stock, Marketbeat Ratings reports. One investment analyst rated the stock with a hold recommendation and six gave the company a buy recommendation. The 12-month average target price among analysts who have reported on the stock over the past year is $49.22.
A number of equity research analysts have recently released reports on the stock. Royal Bank of Canada raised its price target on Evolent Health shares from $40.00 to $44.00 and gave the stock an “outperform” rating in a Wednesday, Aug. 3 report. Piper Sandler raised her price target on Evolent Health shares from $35.00 to $40.00 and gave the stock an “overweight” rating in a Wednesday, Aug. 3 research report. Guggenheim raised its price target on Evolent Health shares to $45.00 in a Monday, August 15 research report. Canaccord Genuity Group raised its price target on Evolent Health shares from $45.00 to $55.00 and gave the stock a “buy” rating in a Thursday, Aug. 4 research report . Finally, JPMorgan Chase & Co. raised its price target on Evolent Health shares from $37.00 to $52.00 and gave the stock an “overweight” rating in a Friday 19 research report. august.
Insider Buying and Selling at Evolent Health
In other news from Evolent Health, General Counsel Jonathan Weinberg sold 14,335 shares in a trade that took place on Friday, August 12. The shares were sold at an average price of $34.96, for a total transaction of $501,151.60. Following the transaction, the General Counsel now directly owns 135,103 shares of the company, valued at $4,723,200.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. In other news, manager Frank J. Williams sold 50,000 shares in a trade that took place on Wednesday, August 24. The stock was sold at an average price of $37.21, for a total transaction of $1,860,500.00. Following the completion of the sale, the director now owns 752,434 shares of the company, valued at $27,998,069.14. The transaction was disclosed in a legal filing with the SEC, accessible via the SEC’s website. Additionally, General Counsel Jonathan Weinberg sold 14,335 shares in a trade that took place on Friday, August 12. The shares were sold at an average price of $34.96, for a total value of $501,151.60. Following the sale, the General Counsel now directly owns 135,103 shares of the company, valued at approximately $4,723,200.88. The disclosure of this sale can be found here. Insiders sold 90,269 shares of the company worth $3,238,910 in the past ninety days. Insiders hold 4.20% of the shares of the company.
Evolutionary Health Institutional Trade
A number of institutional investors have recently changed their positions in EVH. Advisor Group Holdings Inc. increased its stake in shares of Evolent Health by 38.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,055 shares of the technology company valued at $113,000 after buying 1,135 additional shares during the period. BNP Paribas Arbitrage SA increased its equity stake in Evolent Health by 48.0% during the fourth quarter. BNP Paribas Arbitrage SA now owns 27,665 shares of the technology company valued at $765,000 after purchasing an additional 8,976 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Evolent Health by 22.0% during the fourth quarter. Teacher Retirement System of Texas now owns 16,861 shares of the technology company valued at $467,000 after purchasing 3,037 additional shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Evolent Health during the fourth quarter worth approximately $502,000. Finally, Ensign Peak Advisors Inc acquired a new stake in Evolent Health in the fourth quarter valued at $382,000. Hedge funds and other institutional investors own 96.81% of the company’s shares.
Evolent Health Trading down 4.5%
Shares of Evolent Health opened at $35.85 on Friday. Evolent Health has a 12 month minimum of $21.36 and a 12 month maximum of $39.78. The company has a market capitalization of $3.28 billion, a price-earnings ratio of -112.03 and a beta of 1.79. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt ratio of 0.46. The company’s 50-day moving average price is $35.81 and its 200-day moving average price is $31.82.
Evolent Health (NYSE:EVH – Get Rating) last reported quarterly results on Tuesday, August 2. The technology company reported earnings per share (EPS) of $0.02 for the quarter, beating analyst consensus estimates of $0.05 ($0.07). Evolent Health recorded a negative net margin of 2.63% and a positive return on equity of 0.41%. The company posted revenue of $319.94 million for the quarter, versus a consensus estimate of $293.31 million. On average, stock analysts expect Evolent Health to post earnings per share of 0.06 for the current fiscal year.
Evolent Health Company Profile
(Get an evaluation)
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Evolent Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Evolent Health didn’t make the list.
Although Evolent Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here